Compare Hershey Co (HSY) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Twist Bioscience Corp — how do they compare? Hershey Co trades at $162.5 (market cap $32.66B), while Twist Bioscience Corp trades at $161.08 (market cap $10.08B). The key difference: Hershey Co is far larger — about 3.2× Twist Bioscience Corp's market cap, and Hershey Co pays a 3.57% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hershey Co for 135 Days and Twist Bioscience Corp for 27 Days on average.
| HSY | TWST | |
|---|---|---|
Market Cap | $32.66B | $10.08B |
Volume | 1,578,237 | 4,229,037 |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $205.00 |
52-Week Low | $157.61 | $25.45 |
Typical Hold Time | 135 Days | 27 Days |
Enterprise Value | $37.79B | $10.01B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $160.34, down 0.29% on the day, with the stock showing bearish technical signals despite strong recent earnings beats. The company maintains solid profitability with a 12.24% net margin and 32.81% ROE, though 2025 net income declined to $883 million from prior years. Analyst consensus remains cautious with 65.72% hold ratings, but the $204.62 price target suggests 27.6% upside potential. Recent corporate developments include international leadership changes and ongoing brand investments to drive demand.
HSY presents a mixed investment case with attractive valuation upside but near-term headwinds. The stock's current price near support levels offers entry opportunity for dividend investors, with the recent dividend resumption signaling management confidence. However, commodity cost pressures and competitive threats in the consumer staples space create execution risks. Institutional ownership trends show mixed signals with both new positions and reductions in Q2 2026.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
